DB17438InvestigationalCell transplant therapies
EU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.
- Also known as
- EBViNT
- Code names
- EU204
What you can answer from here — as of April 02, 2025
Which companies are running trials of EU204, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account